The National Medical Insurance Administration recently announced the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2023)", which will be officially implemented on January 1, 2024. With this adjustment, a total of 126 drugs have been newly added to the national medical insurance drug catalog. 143 drugs outside the catalog participated in negotiations or bidding, of which 121 drugs were successfully negotiated or bid, with a negotiation success rate of 84.6% and an average price reduction of 61.7%. Reporters from
found that: the number of diabetes drugs has increased, and the burden on patients has been significantly reduced; new rare diseases and new coronavirus drugs have attracted market attention, and experts have called for attention to be paid to whether the "last mile" can be opened. For related pharmaceutical listed companies, they received a "policy red envelope" at the end of the year, and their products in the coming year are expected to be "price-for-volume."
Increased use of diabetes drugs, COVID-19 drugs attract attention
Among the 126 new drugs added in this adjustment, there are 21 kinds of cancer drugs, 17 kinds of drugs for COVID-19 and anti-infection, and 15 kinds of drugs for chronic diseases such as diabetes, mental illness, rheumatism and immunity, which are rare. There are 15 kinds of drugs for diseases (among them, avatinib tablets are also used for tumors), and there are 59 kinds of drugs for other fields. At the same time, a drug that is about to be withdrawn from the market was recalled. After this adjustment, the total number of drugs in the catalog will increase to 3,088, including 1,698 Western medicines and 1,390 Chinese patent medicines. It is reported that since the establishment of the National Medical Insurance Administration, the drug catalog has been adjusted for six consecutive years, and a total of 744 drugs have been added to the national medical insurance drug catalog. At the same time, a number of drugs with uncertain efficacy, easy clinical abuse, or elimination have been removed. Table of contents.
Huang Xinyu, director of the Pharmaceutical Management Department of the National Medical Insurance Administration, said that after this adjustment, the level of protection in the fields of chronic diseases, rare diseases, children's medicines and other fields has been further significantly improved. The success rate of negotiation or bidding and the price reduction are basically the same as in 2022, and the superposition Negotiating price reductions and medical insurance reimbursement factors are expected to reduce the burden on patients by more than 40 billion yuan in the next two years.
In recent years, innovative drugs for chronic diseases have been quickly included in medical insurance through negotiation. Taking drugs for the treatment of diabetes as an example, compared with the 2017 National Medical Insurance Drug Catalog in the new version of the 2023 catalog, the variety of diabetes drugs has doubled. In the 2023 new version of the National Medical Insurance Drug Catalog, there are 82 types of Western medicines for the treatment of diabetes. Among them, since 2017, 41 types of drugs have been adjusted and included in the medical insurance catalog, including 26 types that have been transferred through negotiation, with an average decrease of 60.6%, and 15 types have been transferred directly.
Drugs in the new coronavirus field have also attracted market attention. It is reported that after the implementation of the new version of the medical insurance catalog and combined with the current medical insurance policies in various places, the minimum personal payment amount for the new coronavirus innovative drug Xenoxin will be further reduced. Wang Feng, head of R&D at Simcere Pharmaceuticals, said that Xenoxin will exert greater clinical drug value after entering the medical insurance. Simcere Pharmaceuticals is also further strengthening its product layout and new drug research and development efforts in the anti-infectious field.
Rare disease drugs are still difficult to use and reimburse.
As for the inclusion of rare disease drugs in medical insurance, the National Medical Insurance Administration stated that it has removed the approval period limit for rare disease drugs for three consecutive years in terms of access conditions. Clear preference will be given in the review, calculation and other aspects to support the priority inclusion of qualified drugs for rare diseases in medical insurance. With this adjustment, a total of 15 rare disease drug negotiations/biddings outside the catalog were successfully negotiated, covering 16 rare disease types, and filling the gaps in drug protection for 10 disease types.
However, there is still a "last mile" that needs to be cleared in the implementation of national medical insurance negotiations. For example, problems such as "difficulty in hospital admission", "difficulty in medication" and "difficulty in reimbursement" of drugs still exist. Taking rare diseases as an example, these phenomena exist to a certain extent in this field. Professor Fu Rong, deputy director of Tianjin Medical University General Hospital and director of the Hematology Center, told Guangzhou Daily’s all-media reporters that he hopes to open up a green channel for rare disease drugs so that hospitals can purchase rare disease drugs without too much burden and truly enable rare disease drugs to be provided. Patients’ medications are covered by medical insurance.
Many listed pharmaceutical companies issued announcements to "bring good news"
received "policy red envelopes" at the end of the year. Many listed pharmaceutical companies have recently issued announcements. In addition to disclosing the specific circumstances of some of the company's products being included in the national medical insurance catalog, some industry insiders The possible impact of drug inclusion was also analyzed.
Hengrui Medicine stated that the total sales of the company's drugs included in the national medical insurance catalog in 2022 will be approximately 7.479 billion yuan, and the total sales in the first to third quarter of 2023 will be approximately 5.930 billion yuan. The inclusion of drugs in the national medical insurance catalog is beneficial to the sales of drugs, and the impact on the company's operating performance cannot be estimated for the time being; Xinlitai said that the inclusion of this product in the national medical insurance catalog fully reflects the country's support for innovative drugs with high clinical value and reasonable prices. and recognition. The implementation of the new version of the catalog and the optimization of the "dual-channel" management mechanism for negotiated drugs will be more conducive to drug market promotion and sales, which will contribute to the company's future revenue and profits.
Kanghong Pharmaceutical announced that its Conbercept ophthalmic injection (trade name: "Langmu") and escitalopram oxalate oral solution (trade name: "Bomingxin"), specifications: C20H21FN2O meter: 120ml: 120mg/bottle) has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2023)"; Xinlitai's announcement shows that the company's innovative drug Xinlitan (generic name: Allisartan Equitilate Tablets, specifications are: 80mg/tablet and 240mg/tablet) were renewed through negotiation and included in the scope of Category B of the medical insurance catalog; Enalol® (generic name: Ennadustat tablets, specifications are 1mg/tablet, 2mg/tablet, 4mg/tablet) Through negotiations, the scope of Category B was newly included in the medical insurance catalog; Joincare announced that a total of 210 products of the company and its subsidiaries were included in the "2023 National Medical Insurance Catalog", including 95 Category A and 115 Category B; Yifan Pharmaceuticals The announcement stated that some of the company's products have been included in the "2023 National Medical Insurance Catalog", among which the innovative drug Ibegostim α injection and the original imported drug Tringan cross-linked sodium hyaluronate injection were negotiated for inclusion for the first time, and Maqin Xiaoke granules This time it is adjusted to the regular national medical insurance catalog.
Industrial Securities believes that under the new policy cycle, the innovative drug sector is bullish in the long term as the main line. At present, we can gradually start to pay attention to the bottom reversal opportunities of the innovative drug industry chain (upstream life sciences, CXO). Industrial demand is expected to usher in demand recovery next year.
Reporter Observation
Reporter Observation found that the success rate of negotiation for innovative drugs was as high as 92%. This is exactly the epitome of my country's strong support for the development of innovative drugs. It is reported that my country is urging the timely inclusion of innovative drugs in the medical insurance catalog at reasonable prices and supporting the acceleration of clinical application. In 2023, 25 innovative drugs participated in the negotiations, and 23 were negotiated, with a success rate of 92%. Compared with the overall level, the success rate is 7.4 percentage points higher and the average reduction is 4.4 percentage points lower. The proportion of newly launched drugs in the past five years among the new drugs in the catalog increased from 32% in 2019 to 97.6% in 2023.
The new version of the National Medical Insurance Drug Catalog will be implemented next month. With new hopes in the new year, we hope that after the new version of the catalog is released, designated medical institutions and "dual-channel" retail pharmacies can open up the "last mile" of drug delivery and strengthen the addition of new drugs. Equipped to make the favorable policies of catalog adjustment take effect as soon as possible, so that the insured people can use the good and new drugs included in the medical insurance catalog as soon as possible.
text/Tu Duanyu
editor/Ni Jianing
